A prospective study to evaluate the effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetic patients with chronic kidney disease
Introduction: Recent studies suggest that sodium-glucose cotransporter 2 inhibitors (SGLT2i) are effective at slowing the progression of kidney disease and lowering the risk of kidney failure in people with kidney disease and type 2 diabetes. There is no such study from India. The present study was...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Journal of Diabetology |
| Subjects: | |
| Online Access: | http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2022;volume=13;issue=3;spage=301;epage=304;aulast=Saldanha |
| _version_ | 1811240775859568640 |
|---|---|
| author | Neil Saldanha Mita Shah Monika S Dalal Zaheer Amin Virani Ishan Parekh Hepal Vora Prashant Rajput Shruti Tapiawala Bharat V Shah |
| author_facet | Neil Saldanha Mita Shah Monika S Dalal Zaheer Amin Virani Ishan Parekh Hepal Vora Prashant Rajput Shruti Tapiawala Bharat V Shah |
| author_sort | Neil Saldanha |
| collection | DOAJ |
| description | Introduction: Recent studies suggest that sodium-glucose cotransporter 2 inhibitors (SGLT2i) are effective at slowing the progression of kidney disease and lowering the risk of kidney failure in people with kidney disease and type 2 diabetes. There is no such study from India. The present study was performed to evaluate the effects of SGLT2i in Indian patients with diabetes and chronic kidney disease (CKD). Materials and Methods: This prospective study included 86 patients with diabetes and chronic kidney disease and with an estimated creatinine clearance of >30 mL/minute. Forty-one patients received SGLT2i and 45 patients did not receive SGLT2i. Patients were followed up for at least 12 months. Body mass index (BMI), blood pressure, HbA1c, urine protein to creatinine ratio (UPCR), doubling of serum creatinine and rate of decline of the estimated creatinine clearance were compared between the two groups. Results: The two groups were comparable at baseline in terms of age, sex, blood pressure, BMI, HbA1c, and degree of renal impairment. Over 12 months the UPCR decreased by 0.03 in SGLT2i group and increased by 1.1 in non SGLT2i group (P < 0.05). Doubling of serum creatinine occurred in 4.8% of patients in the SGLT2i group as compared to 18% in the control group (P < 0.05). The rate of decline of the estimated creatinine clearance in the SGLT2i group was 4.9 ml/min/year as compared to 9.4 ml/min/year in the non SGLT2i group (P < 0.05). At 12 months the BMI in the SGLT2i group decreased by 1.49 as compared to 0.12 in the non SGLT2i group (P < 0.05). The blood pressure and HbA1c control were similar in both groups during the study period suggesting that the observed effect was due to SGLT2 inhibition itself and not due to blood pressure or blood glucose control. Conclusion: Our study showed that treatment with SGLT2i had significant renoprotective effects, as shown by a reduction in urinary protein excretion, less percentage of patients developing doubling of serum creatinine, and a slower rate of decline in creatinine clearance. |
| first_indexed | 2024-04-12T13:26:17Z |
| format | Article |
| id | doaj.art-580780cc163546b483e275505f1618de |
| institution | Directory Open Access Journal |
| issn | 2078-7685 |
| language | English |
| last_indexed | 2024-04-12T13:26:17Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Diabetology |
| spelling | doaj.art-580780cc163546b483e275505f1618de2022-12-22T03:31:18ZengWolters Kluwer Medknow PublicationsJournal of Diabetology2078-76852022-01-0113330130410.4103/jod.jod_66_22A prospective study to evaluate the effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetic patients with chronic kidney diseaseNeil SaldanhaMita ShahMonika S DalalZaheer Amin ViraniIshan ParekhHepal VoraPrashant RajputShruti TapiawalaBharat V ShahIntroduction: Recent studies suggest that sodium-glucose cotransporter 2 inhibitors (SGLT2i) are effective at slowing the progression of kidney disease and lowering the risk of kidney failure in people with kidney disease and type 2 diabetes. There is no such study from India. The present study was performed to evaluate the effects of SGLT2i in Indian patients with diabetes and chronic kidney disease (CKD). Materials and Methods: This prospective study included 86 patients with diabetes and chronic kidney disease and with an estimated creatinine clearance of >30 mL/minute. Forty-one patients received SGLT2i and 45 patients did not receive SGLT2i. Patients were followed up for at least 12 months. Body mass index (BMI), blood pressure, HbA1c, urine protein to creatinine ratio (UPCR), doubling of serum creatinine and rate of decline of the estimated creatinine clearance were compared between the two groups. Results: The two groups were comparable at baseline in terms of age, sex, blood pressure, BMI, HbA1c, and degree of renal impairment. Over 12 months the UPCR decreased by 0.03 in SGLT2i group and increased by 1.1 in non SGLT2i group (P < 0.05). Doubling of serum creatinine occurred in 4.8% of patients in the SGLT2i group as compared to 18% in the control group (P < 0.05). The rate of decline of the estimated creatinine clearance in the SGLT2i group was 4.9 ml/min/year as compared to 9.4 ml/min/year in the non SGLT2i group (P < 0.05). At 12 months the BMI in the SGLT2i group decreased by 1.49 as compared to 0.12 in the non SGLT2i group (P < 0.05). The blood pressure and HbA1c control were similar in both groups during the study period suggesting that the observed effect was due to SGLT2 inhibition itself and not due to blood pressure or blood glucose control. Conclusion: Our study showed that treatment with SGLT2i had significant renoprotective effects, as shown by a reduction in urinary protein excretion, less percentage of patients developing doubling of serum creatinine, and a slower rate of decline in creatinine clearance.http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2022;volume=13;issue=3;spage=301;epage=304;aulast=Saldanhachronic kidney diseasediabetes mellitussglt2i |
| spellingShingle | Neil Saldanha Mita Shah Monika S Dalal Zaheer Amin Virani Ishan Parekh Hepal Vora Prashant Rajput Shruti Tapiawala Bharat V Shah A prospective study to evaluate the effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetic patients with chronic kidney disease Journal of Diabetology chronic kidney disease diabetes mellitus sglt2i |
| title | A prospective study to evaluate the effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetic patients with chronic kidney disease |
| title_full | A prospective study to evaluate the effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetic patients with chronic kidney disease |
| title_fullStr | A prospective study to evaluate the effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetic patients with chronic kidney disease |
| title_full_unstemmed | A prospective study to evaluate the effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetic patients with chronic kidney disease |
| title_short | A prospective study to evaluate the effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetic patients with chronic kidney disease |
| title_sort | prospective study to evaluate the effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetic patients with chronic kidney disease |
| topic | chronic kidney disease diabetes mellitus sglt2i |
| url | http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2022;volume=13;issue=3;spage=301;epage=304;aulast=Saldanha |
| work_keys_str_mv | AT neilsaldanha aprospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT mitashah aprospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT monikasdalal aprospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT zaheeraminvirani aprospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT ishanparekh aprospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT hepalvora aprospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT prashantrajput aprospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT shrutitapiawala aprospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT bharatvshah aprospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT neilsaldanha prospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT mitashah prospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT monikasdalal prospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT zaheeraminvirani prospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT ishanparekh prospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT hepalvora prospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT prashantrajput prospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT shrutitapiawala prospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease AT bharatvshah prospectivestudytoevaluatetheeffectsofsodiumglucosecotransporter2inhibitorsintype2diabeticpatientswithchronickidneydisease |